



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

O'MAHONY et al

Atty. Ref.: 3659-69

Serial No. 10/642,606

Group: 1723

Filed: August 19, 2003

Examiner: BIANCO Patricia

For: USER INTERFACE FOR BLOOD TREATMENT DEVICE

\* \* \* \* \*

September 9, 2004

Commissioner for Patents  
P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following are submitted in the above-identified application in compliance with 37  
C.F.R. §§ 1.97 and 1.98:

**INFORMATION DISCLOSURE STATEMENT**


- |                                     |  |          |
|-------------------------------------|--|----------|
| 1.                                  | <b>PTO-1449 Pursuant to 37 CFR 1.97(b)</b><br>[within 3 months of filing or prior to 1st Office Action]  | N/C      |
| X                                   | 2. <b>Statement Pursuant to 37 CFR 1.97(c)</b><br>[before Final Office Action or Allowance]  | N/C      |
| <input type="checkbox"/>            | 3. <b>Fee Payment Pursuant to 37 CFR 1.97(c)</b><br>[before Final Office Action or Allowance]  | \$180.00 |
| <input type="checkbox"/>            | 4. <b>Statement &amp; Fee Payment Pursuant to 37 CFR 1.97(d)</b><br>[before Issue Fee payment]   | \$180.00 |
| <input checked="" type="checkbox"/> | 5. A list of documents on Form PTO-1449 together with copies of each<br>identified document and a translation or a concise explanation of each non-<br>English language document is enclosed herewith. |          |

This paper is submitted in accordance with:

- X
6. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
7. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐
- a) The Statement required by 37 CFR §§1.97(c)(1) and (e) made in item 9 below; or
- X
- b) The fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.
- ☐
8. 37 CFR §1.97(d): [before issue fee payment]; and
- ☐
- a) This is a request for consideration of the subject Information Disclosure Statement. The fee required by 37 CFR §1.17(p) is authorized in item 10 below; and
- ☐
- b) The Statement required by 37 CFR §§1.97(d)(1) and (e) is stated in item 9 below.
- ☐
9. Statement under 37 CFR 1.97(e)
- ☐
- a) Each item of information contained in this Information Disclosure Statement was cited for the first time in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒
10. Please charge all applicable fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:   
Jeffrey H. Nelson  
Reg. No. 30,481

JHN:glf  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100



SEP 09 2004  
(Use several sheets if necessary)  
PATENT & TRADEMARK OFFICE

**SERIAL NO.**

Not yet assigned

O'MAHONY et al

**GROUP**

Not yet assigned

[illegible]

								TRANSLATION	
DOCUMENT				DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

		PRISMA, M60 Set, Instructions for Use
		International Search Report dated March 31, 2003

Date Considered

Form PTO-FB-A820 (Also PTO-1449)